Back to results
US 11,299,782 B2Granted
Methods for predicting anti-cancer response
AssigneesChildren's Medical Center Corporation, Technical University of Denmark, Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc.
InventorsZoltan Szallasi, Nicolai Juul Birkbak, Aron Eklund, Daniel Silver, Zhigang Wang, Andrea Richardson
Life of this patent
Estimating the term…
Abstract
The present invention is based, in part, on the identification of novel methods for defining predictive biomarkers of response to anti-cancer drugs.
Claims8
A method of administering an anti-cancer treatment to a human patient, the method comprising:
- (1) directing a clinical laboratory to
- (a) detect a plurality of chromosomal aberrations in chromosomal segments comprising a plurality of loci in a sample from a human patient, wherein chromosomal aberrations are detected in at least one pair of human chromosomes of a cancer cell of the patient, wherein each of the chromosomal segments is at least 12 Mb in length, extends to and involves the telomere but does not cross the centromere,
- (b) calculate a telomeric imbalance score (NtAI) by summing the number of chromosomal aberrations detected in step (a), and
- (c) communicate an NtAI to the clinician, and
- (2) administering an anti-cancer therapy selected from the group consisting of platinum-comprising therapy, DNA damaging agent comprising therapy, anthracycline-comprising therapy, topoisomerase I inhibitor-comprising therapy and PARP inhibitor comprising therapy to the patient in whose sample an NtAI of at least 8 is calculated.
2 more elements
A method of administering an anti-cancer treatment to a human patient, the method comprising:
- (1) receiving a telomeric imbalance score (NtAI) of at least 8 from a clinical laboratory, wherein the NtAI is determined by the steps of:
- (a) detecting a plurality of chromosomal aberrations in chromosomal segments comprising a plurality of loci in a sample from a human patient, wherein chromosomal aberrations are detected in at least one pair of human chromosomes of a cancer cell of the patient, wherein each of the chromosomal segments is at least 12 Mb in length, extends to and involves the telomere but does not cross the centromere, and
- (b) calculating the NtAI score by summing the number of chromosomal aberrations detected in step (a), and
- (2) administering to said patient an anti-cancer therapy selected from the group consisting of platinum-comprising therapy, DNA damaging agent comprising therapy, anthracycline-comprising therapy, topoisomerase I inhibitor-comprising therapy and PARP inhibitor comprising therapy.
1 more element
Dependencies are inferred from the claim text.